PureTech Health (PRTC) Share Price, News & Analysis

Company Overview

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia. In addition, the company is developing drug delivery platform for oral administration of proteins, peptides, and other difficult-to-deliver payloads; products to generate new human hair follicles and hair; drug delivery platform for drugs that treat inflammation and associated disorders; platform to address immunosenescence; novel targeted immunotherapies for cancer; monoclonal antibodies for immuno-suppressive gamma delta T cells in pancreatic and colorectal cancers, and other solid tumors; novel approaches to enhance delivery and distribution of therapeutics; and digital health technologies, as well as engages in enhancing health through food through the creation of nutrition technology. Further, it is developing a platform and products that take in physiological data from sensors and correlates that data with musical data components; voice-based tools for passive assessment and tracking of patient health; commensal organism-based products for enhancing human health; and technology platform to identify experts in healthcare and other research-based disciplines, as well as engages in identifying healthcare expert networks and reviewing their conversations and content on social media. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: 119.12 to 123.60
• 50-Day Range: 118 to 139.20
• 52-Week Range: 104.71 to 148
• Volume: 294,415 shs
• Average Volume: 1.15 million shs
• Market Capitalization: £294.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 508
• Consensus Rating: Buy

PureTech Health Stock Analysis - MarketRank™

PureTech Health scored higher than 76% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

PureTech Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

PureTech Health has a consensus price target of GBX 508, representing about 320.2% upside from its current price of GBX 120.91.

Amount of Analyst Coverage

PureTech Health has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PureTech Health is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PureTech Health is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PureTech Health has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PRTC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PureTech Health does not currently pay a dividend.

Dividend Growth

PureTech Health does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 1.95

News Sentiment

PureTech Health has a news sentiment score of 1.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for PureTech Health this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for PRTC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of PureTech Health in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net £175,940.31 in company stock, which represents 0.0598% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, PureTech Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought £175,940.31 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

13.35% of the stock of PureTech Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

33.47% of the stock of PureTech Health is held by institutions.

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:PRTC
• CIK: N/A
• Web: puretechhealth.com
• Phone: +1-617-4822333
• Fax: N/A
• Employees: 300
• Year Founded: N/A

Price Target and Rating

• Average Price Target for PureTech Health: GBX 508
• High Price Target: GBX 508
• Low Price Target: GBX 508
• Potential Upside/Downside: +320.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£91.86 million
• Net Margins: -2,355.32%
• Pretax Margin: N/A
• Return on Equity: -31.98%
• Return on Assets: -13.39%

Debt

• Debt-to-Equity Ratio: 6.33
• Current Ratio: 6.59
• Quick Ratio: 2.51

Sales & Book Value

• Annual Sales: £4.66 million
• Price / Sales: 63.17
• Cash Flow: GBX 56.45 per share
• Price / Cash Flow: 2.14
• Book Value: GBX 113.55 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 243,418,000
• Free Float: N/A
• Market Cap: £294.31 million
• Optionable: Not Optionable
• Beta: 0.79